Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 30, 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific transaction notification and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific increase in the notional allocation of American Depositary Shares (ADSs) within a retirement plan due to a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Important Facts for Investors
- Transaction Type: Increase in notional allocation of GSK ADSs within the US Retirement Savings Plan.
- Involved Parties: Dr. M M Slaoui (Director/PDMR) and Dr. K Slaoui (Connected Person).
- Transaction Details: 4 ADSs allocated on April 27, 2012, at a price of $46.51 per ADS.
- Trigger Event: Revaluation of the cash element of the notional investment held in the plan.
- Financial Data: No financial performance data is included in this specific filing.